medigraphic.com
ISSN 1028-9933 (Electronic)

2020, Number 4

<< Back Next >>

RIC 2020; 99 (4)

Botulinum toxin type A efficient treatment in patients with hemifacial spasm, Guantanamo 2018-2019

Marzo-Ramírez T, Mecías-Díaz T

Language: Spanish
References: 20
Page: 359-366
PDF size: 627.29 Kb.


ABSTRACT

Introduction: no research records were found addressing the results of the application of botulinum toxin type A in patients with hemifacial spasm in Guantanamo province.
Objective: to evaluate the therapeutic results of the application of botulinum toxin type A in patients with hemifacial spasm treated in a Neurology consultation.
Method: a descriptive and longitudinal study was carried out in 21 patients attended in Neurology service with hemifacial spasm and botulinum toxin type A treatment, from January 2018 to January 2019. The variables studied were: age, gender, hemiface affected, latency period, duration, disappearance of the clinical effects of botulinum toxin type A, and percentage of functional disability in patients when applying the disability scale before and after the treatment.
Results: female cases predominated (57.1%), ages over 55 years (57.14 %), the most common affected side of the face was the left, with 57.14 %, the latency period of botulinum toxin type A was between the third to the tenth day in 14 of the patients (66.67 %), the maximum time of duration of treatment ranged from one to two months (57.14 %), and the disappearance of the therapeutic effect of the toxin in the patients was between the third to the fourth month (52.38%). After the application of the clinical assessment scale of hemifacial spasm, a decrease in the percentage of patients with functional disability was evidenced.
Conclusions: botulinum toxin type A is effective in the treatment of hemifacial spasm.


REFERENCES

  1. Fhans, Jankovic J, Mark H. Restlesslegs and peripheral movement disorder Section III Hyperkinetic disorders. En Principles and Practices of Movements Disorders. 2aed. Philadelfia: Elsevier Saunders; 2011. p. 500.

  2. Campero A,Cuervo-ArangoI, Barrenechea. Descompresión microvascular en espasmo hemifacial: reporte de 13 casos y revisión de la literatura. Surg Neurol Int [en línea]. 2016 [citado 20 Ago 2020]; 7(Suppl 8):201207. Disponible en: http://surgicalneurologyint. com/Descompresion-microvascularen- espasmo-hemifacial:-Rporte-de-13-casos-y-revision-de-la-literatura/

  3. Luna Arnez JC, Arostegui Bustillos P, Alanes Fernández AM. Uso de Toxina Botulínica en Espasmo Hemifacial: a propósito de un caso. Rev Méd La Paz [en línea]. 2016 Jul-Dic [citado 7 Ago 2020]; 22(2):56-59. Disponible en: http://www. scielo. org. bo/pdfrmcmlp/v22n2/v22n2_a10. pdf

  4. Marín Naranjo RM. El uso de toxina botulínica en el tratamiento de la neuralgia del trigémino (V par craneal). Odovtos [en línea]. 2018 [citado 23 Ago 2020]; 20(3):43-50. Disponible en: http://www. scielo. sa. cr/scielo. php?script=sci_arttext&pid=S2215-34112018000300043&lng=en

  5. Caro J, Fuentes N, Iñiguez R. Evidencia y uso actual de toxina botulínica en patología otorrinolaringológica. Rev Otorrinolaringol Cir Cab Cuel [en línea]. 2015 Abr [citado 23 Ago 2020]; 75(1):67-76. Disponible en: https://scielo. conicyt. cl/scielo. php?script=sci_arttext&pid=S0718- 48162015000100011&lng=es

  6. Orsini M, Leite MA, Chung TM, Bocca W, de Souza JA, de Souza OG, et al. Botulinum Neurotoxin type A in Neurology: Update. Neurol Int [en línea]. 2015 [citado 20 Ago 2020]; 7(2): [aprox. 8 p. ]. Disponible en: https://www. ncbi. nlm. nih. gov/pmc/articles/PMC4591494/

  7. Molina J, González J, Bermejo Pareja F, Martínez Martín P. Trastornos del movimiento. II. Hipercinesias y otros trastornos del movimiento. En: Bermejo Pareja F, Porta-Etessam J, Díaz-Guzmán J, Martínez- Martín P, editores. Más de cien escalas en Neurología [en línea]. 2aed. España: Aula Médica; 2008. [citado 5 sep 2020]. p. 250. Disponible en: http://www. neuroloxia. com/wpcontent/uploads/2009/06/Escalas_en_neurologia_marzo. pdf

  8. Lee JA, Kim KH, Park K. Natural History of Untreated Hemifacial Spasm: A Study of 104 Consecutive patients over 5 years. Stereotac Funct Neurosurg [en línea]. 2017 [citado 27 Ago 2020]; 95:21-25. Disponible en: https://www. karger. com/Article/Fulltext/453276

  9. Bentivoglio AR, LalongoT, Bove F, De Nigris F, Fasano A. Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci [en línea]. 2012 [citado 17 Jul 2020]; 33:261-7. Disponible en: https://pubmed. ncbi. nlm. nih. gov/21710123/

  10. Chaudhry N, Srivastva A, Joshi L. Hemifacial spasm : The past, present and future. J Neurol Sci [en línea]. 2015 [citado 1 Ago 2020]; 356(1-2):27-31. Disponible en: https://pubmed. ncbi. nlm. nih. gov/26111430/

  11. Mesa Y, Hernández TE, Parada Y. Eficacia y seguridad del uso de la Toxina botulínica ante otras alternativas medicamentosas en pacientes con distonías focales. Rev Hab Cienc Méd [en línea]. 2016 [citado 11 Feb 2020]; 15(3):348-362. Disponible en: https://www. medigraphic. com/cgibin/new/resumen. cgi?IDARTICULO=66496

  12. Wickwar S, McBain H, Newman SP, Hirani SP, Hurt C, Dunlop N, et al. Effectiveness and costeffectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial. Trials [en línea]. 2016 [citado 24 Jul 2020]; 17:129. Disponible en: https://pubmed. ncbi. nlm. nih. gov/26961367/

  13. Karp BI, Alter K. Botulinum Toxin Treatmen to Blepharospasm, Oromandibular/ Orofacial Dystonia, and Hemifacial Spasm. Semin Neurol [en línea] . 2016 [citado 20 Jul 2020]; 36:84-91. Disponible en : https://pubmed. ncbi. nlm. nih. gov/26866500/

  14. Mette Batisti JP,Kleinfelder Fadini AD,Bassalobre Gallini N,Moro A,Pupi Munhoz R, Ghizoni Teive HA. Treatment of hemifacial spasm with botulinum toxin a : effective,long lasting and well tolerated. Arq Neuropsiq [en línea]. 2017 [citado 20 Ago 2020]; 75(2):87-91. Disponible en: https://scielo. php?scrip=sci_arttexxt&pid=S0004282X2017000200003

  15. Castro F, Castro G, CarielloJulio A, Felberg S, Hentona M. Influência da toxina botulínica tipo A na função lacrimal de pacientes com distonias faciais. Arq Bras Oftalmol [en línea]. 2010 [citado 2017 Feb 11]; 73(5):405-408. Disponible en: http://www. scielo. br/scielo. php?script=sci_arttext&pid=S000427492010000500003&lng=pt

  16. Rodríguez-Aymoro E, Castro-Jiménez M, Maragoto-Rizo C. Uso de Toxina Botulínica Tipo A en Pacientes con Espasmo Hemifacial en Cuba. Rev Ecuat Neurol [en línea]. 2017 [citado 19 Jun 2020]; 26(3):[aprox. 9 p. ]. Disponible en: http://scielo. senescyt. gob. ec/scielo. php?script=sci_arttext&pid=S2631-25812017000200235

  17. Chaná P, Kunstman C, Benavides O, Daniel Muñoz DS, Tapia-Núñez J. Tratamiento del blefaroespasmo y Síndrome de Meige con toxina botulínica. Experiencia y seguimiento en 18 casos. Rev Ecuat Neurol [en línea]. 2008 [citado Mayo 2020]; 17(1-3):[aprox. 12 p. ]. Disponible en : http://revecuatneurol. com/wpcontent/uploads/2015/06/Blefaroespas

  18. Sorgun MH, Yilmaz R, Akin YA, Mercan FN, Akbostanci MC. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci [en línea]. 2015 [citado 19 Jun 2020]; 22(8):1319-25. Disponible en: https://pubmed. ncbi. nlm. nih. gov/26100157/

  19. Huang XF, Wang KY, Liang ZH, Du RR, Zhou LN. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China. Eur Neurol [en línea] 2015 [citado 19 Jun 2020]; 73(5-6):337-41. Disponible en: https://www. karger. com/Article/Abstract/381707

  20. Perez-Garcia I, Jimenez-Fandino Otálora A. Toxina botulínica aplicada bajo guía ecográfica en el tratamiento de la sialorrea: reporte de dos casos. Univ Med [en línea]. 2016 [citado 23 Ago 2020]; 57(2):264-72. Doi: http://dx. doi. org/10. 11144/Javeriana. umed57-tba




2020     |     www.medigraphic.com